Please assess the completion status of the following clinical trial:

Trial Title: Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is \> 18 years of age~2. Diagnosis of primary breast cancer with possible lymph node metastases~3. Availability of results from HER2 status previously determined on material from the primary tumor, either~   1. HER2-positive, defined as a immunohistochemical test score of 3+ or FISH positive or~  2. HER2-negative, defined as a immunohistochemical test score of 0 or 1+; or else if 2+ then FISH negative~4. Volumetrically quantifiable tumour lesions on CT or MRI, with at least one lesion \> 1.0 cm in greatest diameter outside of the liver and kidneys~5. Hematological, liver and renal function test results within the following limits:~   * White blood cell count: \> 2.0 x 10\^9/L~  * Haemoglobin: \> 80 g/L~  * Platelets: \> 50.0 x 10\^9/L~  * Bilirubin =\< 2.0 times Upper Limit of Normal~  * Serum creatinine: Within Normal Limits~6. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination~7. Subject is capable to undergo the diagnostic investigations to be performed in the study~8. Informed consent~Exclusion Criteria:~1. Second, non-breast malignancy~2. Active current autoimmune disease or history of autoimmune disease~3. Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening)~4. Known HIV positive or chronically active hepatitis B or C~5. Administration of other investigational medicinal product within 30 days of screening~6. Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- The tested injected doses of 99mTc-HE3-G3 1000 μg (Type: EXPERIMENTAL): At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 1000 μg.~Subjects withdrawn from the study for any reason will be replaced.
- The tested injected doses of 99mTc-HE3-G3 2000 μg (Type: EXPERIMENTAL): At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 2000 μg.~Subjects withdrawn from the study for any reason will be replaced.
- The tested injected doses of 99mTc-HE3-G3 3000 μg (Type: EXPERIMENTAL): At least five (5) evaluable subjects with HER2-positive status and at least five (5) subjects with HER2-negative status have to be enrolled in the study for each tested protein dose. The tested injected dose 3000 μg.~Subjects withdrawn from the study for any reason will be replaced.

Based on this trial design, predict the completion outcome and termination type (if applicable).